ROCHE PROVIDES UPDATE ON BITPERTIN STUDIES

     (The following press release from Roche Holding AG was received by e-mail.  The sender verified the statement.)  Roche provides update on the first two of six phase III studies of bitopertin  in schizophrenia • Two phase III studies evaluating bitopertin for persistent, predominant  negative symptoms of schizophrenia did not meet their primary endpoints; third  study is ongoing • Three phase III studies evaluating bitopertin for sub-optimally controlled  symptoms of schizophrenia are ongoing  Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that two phase III studies  of its investigational medicine bitopertin (RG1678) in adults with persistent,  predominant negative symptoms of schizophrenia failed to meet their primary  endpoints, based on the negative symptoms factor score of the positive and  negative symptom scale (PANSS). Negative symptoms include social withdrawal and  lack of motivation.  In the studies, adding bitopertin to antipsychotic therapy did not  significantly reduce negative symptoms at 24 weeks compared to placebo.  Bitopertin was generally well tolerated and its overall safety profile was  similar to that seen in the previously reported phase II trial (NN20372).   A third phase III study evaluating bitopertin for persistent, predominant  negative symptoms of schizophrenia is ongoing. In addition, three phase III  studies investigating bitopertin for sub-optimally controlled symptoms of  schizophrenia are in progress. Sub-optimally controlled symptoms, such as  hallucinations and delusions, are symptoms that do not resolve despite  treatment with an antipsychotic.  “These results are disappointing for people with negative symptoms because more  effective treatments are needed for these debilitating effects of  schizophrenia,” said Sandra Horning, M.D., Chief Medical Officer and Head of  Global Product Development at Roche. “We will await data from the remaining  bitopertin studies in schizophrenia before deciding on next steps.” more  With best regards, Roche Group Media Relations  Roche Group Media Relations Grenzacherstrasse 124 4070 Basel, Switzerland  Phone: +41 61 688 88 88 Fax: +41 61 688 27 75 mailto:roche.mediarelations@roche.com www.roche.com  Confidentiality Note: This message is intended only for the use of the named  recipient(s) and may contain confidential and/or privileged information. If you  are not the intended recipient, please contact the sender and delete this  message. Any unauthorized use of the information contained in this message is  prohibited.